NEW YORK--(BUSINESS WIRE)--Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B (HBV) and hepatitis D (HDV) infection, today announced that Dr. Andrew Vaillant, Chief Scientific Officer will be presenting at two scientific conferences in June.
Help employers find you! Check out all the jobs and post your resume.
